NovoCure Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.
| Earnings Date | 2/25/2027 |
As of September 30, 2026, NovoCure Ltd. has 116.91M shares outstanding.
| Shares Outstanding | 116.91M |
As of September 30, 2026, NovoCure Ltd. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.49 |
| Quick Ratio | 2.30 |
| Debt / Equity | 66.04 |
| Debt / EBITDA | -2.15 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a negative return on equity (ROE) of -35.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.12, reflecting losses generated across the asset base. The company generates approximately 8.16M in revenue per employee across its workforce of 1,605.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.18 indicates how many times NovoCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -35.18 |
| Return on Assets (ROA) | -11.12 |
| Revenue Per Employee | 8.16M |
| Employee Count | 1,605.00 |
| Inventory Turnover | 4.18 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. recorded an income tax benefit of -159.16M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.36B and -2.20B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -159.16M |
As of the close on November 6, 2026, NovoCure Ltd.'s stock has declined approximately 9.77% over the past 52 weeks.
| 52-Week Price Change | -9.77% |
Over the twelve months ended September 30, 2026, NovoCure Ltd. generated 13.10B in revenue and converted that into -2.20B in net income, yielding earnings per share of -19.15. EBITDA reached -1.94B, while operating income came in at -2.25B.
| Revenue | 13.10B |
| Gross Profit | 10.09B |
| Operating Income | -2.25B |
| Pretax Income | -2.36B |
| Net Income | -2.20B |
| EBITDA | -1.94B |
| EBIT | -2.25B |
| Earnings Per Share (EPS) | -19.15 |
As of September 30, 2026, NovoCure Ltd. holds 8.37B in cash and equivalents against 4.18B in total debt, resulting in a net debt position of 1.80B. Total book value stands at 6.33B, with working capital of 7.27B providing operational flexibility.
| Cash & Cash Equivalents | 8.37B |
| Total Debt | 4.18B |
| Net Debt | 1.80B |
| Equity (Book Value) | 6.33B |
| Book Value Per Share | 54.15 |
| Working Capital | 7.27B |
NovoCure Ltd. produced -13.04M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -431.29M in capital expenditures, free cash flow totaled -444.33M - equivalent to -3.87 per share.
| Operating Cash Flow | -13.04M |
| Capital Expenditures | -431.29M |
| Free Cash Flow | -444.33M |
| FCF Per Share | -3.87 |
Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a gross margin of 77.02, reflecting its pricing power and cost economics. The operating margin of -17.17 and net profit margin of -16.78 provide insight into operational efficiency.
| Gross Margin | 77.02 |
| Operating Margin | -17.17 |
| Pretax Margin | -18.00 |
| Profit Margin | -16.78 |
| EBITDA Margin | -14.82 |
Already premium?